loading
Precedente Chiudi:
$13.49
Aprire:
$13.46
Volume 24 ore:
61,304
Relative Volume:
0.07
Capitalizzazione di mercato:
$558.46M
Reddito:
-
Utile/perdita netta:
$-168.05M
Rapporto P/E:
-2.6524
EPS:
-5.13
Flusso di cassa netto:
$-146.15M
1 W Prestazione:
-0.59%
1M Prestazione:
-6.79%
6M Prestazione:
-20.68%
1 anno Prestazione:
-70.76%
Intervallo 1D:
Value
$13.42
$13.63
Intervallo di 1 settimana:
Value
$13.31
$13.80
Portata 52W:
Value
$9.12
$72.37

Keros Therapeutics Inc Stock (KROS) Company Profile

Name
Nome
Keros Therapeutics Inc
Name
Telefono
617-314-6297
Name
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Name
Dipendente
163
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
KROS's Discussions on Twitter

Confronta KROS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
KROS
Keros Therapeutics Inc
13.62 558.46M 0 -168.05M -146.15M -5.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
440.96 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
512.35 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
310.31 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
537.28 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
256.61 28.51B 3.81B -644.79M -669.77M -6.24

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-10 Downgrade BofA Securities Buy → Neutral
2025-01-21 Downgrade Cantor Fitzgerald Overweight → Neutral
2025-01-17 Downgrade Wedbush Outperform → Neutral
2024-12-16 Downgrade Guggenheim Buy → Neutral
2024-12-16 Reiterato Oppenheimer Outperform
2024-12-13 Reiterato H.C. Wainwright Buy
2024-12-12 Downgrade BTIG Research Buy → Neutral
2024-12-12 Downgrade TD Cowen Buy → Hold
2024-12-12 Downgrade William Blair Outperform → Mkt Perform
2024-11-05 Iniziato Jefferies Buy
2024-10-24 Iniziato Cantor Fitzgerald Overweight
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-09-23 Iniziato Guggenheim Buy
2024-06-25 Iniziato Oppenheimer Outperform
2024-02-21 Iniziato William Blair Outperform
2023-12-08 Iniziato Wells Fargo Overweight
2023-07-31 Iniziato Wedbush Outperform
2023-07-26 Iniziato BofA Securities Buy
2023-02-14 Iniziato Cowen Outperform
2022-10-18 Iniziato Truist Buy
2022-07-26 Iniziato BTIG Research Buy
2020-12-08 Reiterato H.C. Wainwright Buy
2020-05-04 Iniziato H.C. Wainwright Buy
2020-05-04 Iniziato Jefferies Buy
2020-05-04 Iniziato Piper Sandler Overweight
2020-05-04 Iniziato SVB Leerink Outperform
Mostra tutto

Keros Therapeutics Inc Borsa (KROS) Ultime notizie

pulisher
Jun 18, 2025

(KROS) Trading Report - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 17, 2025

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN

Jun 17, 2025
pulisher
Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025
pulisher
Jun 14, 2025

Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $30.56 - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

Bank of America Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral - MarketBeat

Jun 13, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Buys 23,342 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Keros Therapeutics (NASDAQ:KROS) Shares Gap DownTime to Sell? - MarketBeat

Jun 12, 2025
pulisher
Jun 11, 2025

Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Bank of America - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst - Benzinga

Jun 10, 2025
pulisher
Jun 10, 2025

Keros Therapeutics Hindered by KER-065 Concerns Despite 'Intriguing' Pipeline, BofA Says - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32 - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

KROS: Keros Therapeutics Receives Downgrade from B of A Securities | KROS Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Keros Therapeutics (KROS) Downgraded to Neutral by BofA Analyst - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Keros Therapeutics (KROS) Downgraded to Neutral by BofA Analyst | KROS Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

ADAR1 Demands Bigger Payouts From Keros Therapeutics - Finimize

Jun 10, 2025
pulisher
Jun 09, 2025

Keros Therapeutics to return $375 million to shareholders By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

ADAR1 Capital Management Calls For Keros Therapeutics To Return $475 Mln To Stockholders By Q3 - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Directors Face Massive Shareholder Revolt: ADAR1 Pushes for $475M Dividend and Board Overhaul - Stock Titan

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics (KROS) to Return $375M Capital to Shareholders | KROS Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics Concludes Strategic Alternatives Review - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Keros to Return $375 Million to Shareholders Following Strategic Review - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Announces Return of $375 Million in Excess Capital to Stockholders - The Manila Times

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics to return $375 million to shareholders - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics Announces $375 Million Capital Return Plan Following Strategic Review - Nasdaq

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Concludes Strategic Review: Massive $375M Shareholder Return While Advancing DMD Drug Development - Stock Titan

Jun 09, 2025
pulisher
Jun 09, 2025

Nuveen Asset Management LLC Sells 181,863 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Wellington Management Group LLP - Defense World

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Position Boosted by Two Sigma Investments LP - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

Two Sigma Advisers LP Has $328,000 Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Nuveen Asset Management LLC Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 05, 2025
pulisher
Jun 03, 2025

Keros Therapeutics (NASDAQ:KROS) Receives Neutral Rating from Wedbush - MarketBeat

Jun 03, 2025
pulisher
Jun 02, 2025

Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.9%Should You Sell? - MarketBeat

Jun 02, 2025
pulisher
Jun 02, 2025

ProShare Advisors LLC Purchases 2,764 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Bank of America Corp DE - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

D. E. Shaw & Co. Inc. Cuts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Jun 01, 2025
pulisher
Jun 01, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,386 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Deutsche Bank AG Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

May 31, 2025
pulisher
May 30, 2025

KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | - GuruFocus

May 30, 2025
pulisher
May 30, 2025

KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | KROS Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

TFG Asset Management GP Ltd Acquires New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

May 30, 2025
pulisher
May 30, 2025

Keros Therapeutics halts PAH drug development, cuts workforce By Investing.com - Investing.com South Africa

May 30, 2025

Keros Therapeutics Inc Azioni (KROS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Keros Therapeutics Inc Azioni (KROS) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Seehra Jasbir
CHIEF EXECUTIVE OFFICER
Apr 04 '25
Option Exercise
0.30
49,367
14,810
302,223
GORDON CARL L
Director
Aug 13 '24
Sale
44.01
250,000
11,002,500
119,522
ORBIMED ADVISORS LLC
Director
Aug 13 '24
Sale
44.01
250,000
11,002,500
119,522
$20.89
price down icon 0.66%
$35.12
price up icon 1.05%
$20.60
price up icon 1.48%
$102.01
price down icon 1.01%
$105.16
price down icon 1.24%
biotechnology ONC
$258.31
price up icon 6.02%
Capitalizzazione:     |  Volume (24 ore):